TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.

The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."

• Presentation Date: Tuesday, May 13
• Time: 6:00 - 7:30 p.m. Central Time
• Location: Poster Hall, Hall I2
• Abstract Number: AMA1180

The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.

Positive

• Acceptance of research abstract for presentation at major industry conference (ASGCT) showcasing CD45 as potential universal target for TCR-T cell therapy
• Research presentation indicates progress in company's TCR-T therapy development pipeline

Negative

• None.

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually.

Poster Presentation Details:

Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation
Authors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, Rakshi Bala, Vivin Karthik, Debanjan Goswamy, Hannah Bader, Alok Das Mahopatra, Daniel C Pollacksmith, Shubhangi Kamalia, Nivya Sharma, Victor Ospina, Sanket Revadkar, Drashti Shah, Ryan E Kritzer, Hana Husic, Shobitha Jillella, Nicole Ladd, Shoshana Bloom, Rachel Lent, Prachi Dhanania, Chandan K Pavuluri, Carolyn Hardy, Alexander Cristofaro, Zhonghua Zhu, Livio Dukaj, Kimberly M Cirelli, Antoine Boudot, Mollie M Jurewicz, Cagan Gurer
Abstract Number: AMA1180
Session Date/Time: Tuesday, May 13; 6:00 - 7:30 p.m. Central Time
Location: Poster Hall, Hall I2

A copy of the presentation materials will be added to the “Publications” section of the Company’s website at tscan.com once the presentation has concluded.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When will TScan Therapeutics (TCRX) present at ASGCT 2025?

TScan Therapeutics will present on Tuesday, May 13, 2025, from 6:00 - 7:30 p.m. Central Time at the ASGCT Annual Meeting in New Orleans, LA. The presentation will be held in Poster Hall, Hall I2.

What is TScan Therapeutics (TCRX) presenting at ASGCT 2025?

TScan will present research on CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation, with abstract number AMA1180.

Where can investors find TScan (TCRX) ASGCT presentation materials?

The presentation materials will be available in the 'Publications' section of TScan's website at tscan.com after the presentation concludes.

What type of therapy is TScan Therapeutics (TCRX) developing?

TScan Therapeutics is developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for treating cancer patients.

Is the ASGCT 2025 conference where TScan (TCRX) is presenting available virtually?

Yes, the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting will be held both in-person in New Orleans, LA and virtually from May 13-17, 2025.